Vivos Therapeutics Inc. VVOS Archives

TuesdayNov 16, 2021 10:40 am

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q3 2021 Financial, Operational Report

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults, has released is third-quarter 2021 financial report; the company also reported on operational highlights. The report noted that VVOS Q3 revenue increase more than 38% year over year, reaching $4.5 million for the third quarter of 2021 and $12.5 million for the nine months ended Sept. 30, 2021 as compared to $3.3 million and $9.8 million for the three and nine months for the same period last…

MondayNov 15, 2021 10:04 am

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Participation at Q4 Virtual Investor Summit

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”), will be presenting at the upcoming Q4 Virtual Investor Summit. The summit is scheduled for Nov. 17, 2021. Vivos CEO Kirk Huntsman, chief financial officer Brad Amman, and investor relations officer Ed Loew will provide key information about the company during a life webcast slated to begin at 11:45 a.m. EST. To view the full presentation, visit https://ibn.fm/NRKmq To view the full press release, visit https://ibn.fm/ioAfi About Vivos Therapeutics Inc. Vivos Therapeutics is a medical technology company focused…

TuesdayNov 09, 2021 10:20 am

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Scheduled Release of Q3 2021 Financial Results, Conference Call

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults, today announced that it plans to release financial results for the third quarter ended Sept. 30, 2021, after market close on Monday, Nov. 15, 2021. Vivos will host a conference call the same day at 5:00 p.m. Eastern Time to review the results and provide an overview of the company’s recent milestones and growth strategy. Interested parties may access a live webcast via the Vivos’ website and join the…

FridayOct 22, 2021 9:43 am

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Present at Benzinga Global Small Cap Conference

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, today announced that its chairman and CEO Kirk Huntsman and CFO Brad Amman will be presenting at the online Benzinga Global Small Cap Conference. The event is slated to take place from Oct. 27-28, 2021, with Vivos’ presentation scheduled to begin at 12:15 p.m. ET on Wednesday, Oct. 27. Interested investors should visit https://ibn.fm/jz90E to register for a free spectator pass. A replay will be available for view following…

WednesdayOct 20, 2021 3:28 pm

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Showcasing Innovations in OSA Treatment at 2021 Annual Breathing Wellness Conference

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, has announced the commencement of the 3rd-annual Breathing Wellness Conference presented by The Vivos Institute. The event is taking place at Caesars Palace in Las Vegas, Nevada, from Oct. 20-23, 2021, where dentists and medical doctors from around the world will hear from the industry’s top experts on OSA about its impact on chronic conditions such as heart disease, chronic fatigue and dementia. Attendees will also have the opportunity learn how innovations…

TuesdayOct 19, 2021 2:20 pm

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS), Candid to Bring Airway and Sleep, Oral Health, Orthodontic Therapy Together in Comprehensive Solution

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, and Candid Care Co., a digital platform for oral healthcare, have announced a new collaboration. Under the partnership, the companies will seek to provide patients with a comprehensive, whole-mouth solution to diagnose and treat OSA in adult patients and provide orthodontic treatment from the same provider network. Additionally, under the agreement, Vivos and Candid will join forces to explore new research and development opportunities for device development and other alliances related to…

MondayOct 18, 2021 11:57 am

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS), Candid Collaborate to Deliver Comprehensive Treatment Solution

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, and Candid Care Co., a digital platform for oral healthcare, today announced a new collaboration. The partnership will seek to provide patients with a comprehensive, whole-mouth solution to diagnose and treat OSA in adult patients and provide orthodontic treatment from the same provider network. “By teaming with Candid, we are aiming to provide patients with access not only to our highly effective Vivos System, but also simultaneous access to CandidPro’s novel orthodontic…

WednesdayOct 13, 2021 10:35 am

QualityStocksNewsBreaks – Vivos Therapeutics Inc.’s (NASDAQ: VVOS) Guides Demonstrate Significant Reduction of Pediatric Tooth Decay in Peer-Reviewed Study

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (“OSA”), today announced results from a peer-reviewed, published study by an independent dentist. The findings demonstrate a significant reduction of tooth decay in pediatric patients after undergoing treatment using the company’s FDA Class 1 registered Vivos Guide, a flexible, BPA-free base polymer intraoral device. A preformed positioner intended to prevent a child’s teeth from shifting and may seal the lips to convert mouth breathing to nose breathing, the Vivos Guide is worn…

ThursdaySep 23, 2021 9:54 am

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Forms Medical Consortium to Advance OSA Technology

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (“OSA”), today announced the official formation of the Vivos Medical Consortium. According to the update, this physician working group, led by Drs. Clete Kushida of Stanford University and Cecilia Wu of the University of Alberta, will collaborate to advance Vivos’ OSA technology capabilities. “Every specialty in medicine deals with the negative impact of obstructive sleep apnea in some way, with the end stage of untreated sleep apnea including diminished quality of life,…

WednesdaySep 22, 2021 12:29 pm

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Present at Benzinga Healthcare Small Cap Conference

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (“OSA”), today announced that its chairman and CEO Kirk Huntsman and CFO Brad Amman will be presenting at the online Benzinga Healthcare Small Cap Conference at 2:20 pm ET on Wednesday, Sept. 29, 2021. The event is scheduled to take place from Sept. 29-30, 2021. Investors interested in joining the Vivos presentation should visit https://ibn.fm/JFY3h to register for a free spectator pass. A replay of the presentation will be available for view…

Site Search

Company Search

Tag: Vivos Therapeutics Inc. VVOS